Abstract: Disclosed are cationic lipids which are compounds of Formula (I?). Cationic lipids provided herein can be useful for delivery and expression of mRNA and encoded protein, e.g., as a component of liposomal delivery vehicle, and accordingly can be useful for treating various diseases, disorders and conditions, such as those associated with deficiency of one or more proteins.

Abstract: A process can be used for preparing nanoparticles containing at least one bio-resorbable polyester. The nanoparticles are in the form of a powder with a Z-Average particle size Dz in the range of 1 to 450 nm, and with a polydispersity index PDI in the range of 0.01 to 0.5. The process involves emulsion-solvent extraction or emulsion-solvent evaporation, and application of ultrasonic sound.

Abstract: The present invention relates to a biodegradable multilayer nanocapsule for the delivery of at least one biologically active agent into at least one target cell consisting of at least two layers of at least two biodegradable polymers which are laid one onto the other and whereby the biologically active agent is layered onto a layer of a biodegradable polymer and covered with a further layer of a biodegradable polymer, whereby one biologically active agent is a nucleic acid.

Abstract: The present disclosure relates to a nanoemulsion composition of oxygen gas sustained release and method for preparing the same, and provides a nanoemulsion composition of oxygen gas sustained release and method for preparing the same, including a water phase part containing water, and an oil phase part dispersed in the water phase part and made of nanoparticle containing a perfluorocarbon compound, wherein the oil phase part contains oxygen gas, and the oxygen gas is released in sustained release. According to the present disclosure, there are advantages of preventing hair loss or promoting hair growth by increasing the amount of oxygen gas supplied to the hair bulb and the oxygen release time from the hair bulb.

Abstract: An orally administered dosage form that facilitates delivery of an agent locally in the buccal cavity for a sustained period of time includes mucoadhesive particles that are made of at least a mucoadhesive material combined with the agent, and which are dispersed in a disintegrating film. The dosage form is capable of delivering an agent to a patient at the desired oral mucosa site over an extended period of time while reducing patient discomfort or annoyance associated with conventional sustained release mucoadhesive films that must reside on the oral mucosa during the period of sustained release.

Abstract: This application is directed to methods which allow for encapsulation of an array of biological materials under physiological conditions that are relevant given a biological context and the compositions made using those methods. These reconstituted biological materials encompass: a) purified proteins that can bind to the lipid membranes inside and outside of vesicles based on the electrostatic charge; b) purified cytosolic proteins that position themselves in the lumen of the vesicles, c) mammalian cell extracts with an array of cytosolic protein content, among other contents and d) small biological molecules such as DNA and RNA as well as fluorescent dyes/probes. These vesicles can be used to simulate cells in drug discovery methods as well as useful in administering drugs and other compositions to cells in vitro and in vivo.

Abstract: A method for producing uniform-size liposomes is provided. The liposomes are coated with a sorting agent to yield a plurality of density-modified liposomes of different sizes. These liposomes are then separated using a densitometric method. The sorting agent includes both a density-modifying moiety and a targeting moiety.

Abstract: A spirooxindole nanoformulation includes a proniosome loaded with a spirooxindole derivative.

Abstract: Provided are a nanoliposome-microbubble conjugate in which a drug for hair loss treatment such as finasteride, minoxidil, dutasteride, etc. is encapsulated in a nanoliposome and a composition for alleviating or treating hair loss containing the same. Since an orally administered agent such as finasteride, currently useful as a drug for hair loss treatment, causes side effects, drug delivery through scalp application is most desirable, but the drug is not delivered to hair follicle cells through scalp application alone. Since a drug for hair loss treatment useful as an external preparation for skin causes various side effects, the concentration thereof that is used needs to be further lowered. The above nanoliposome-microbubble conjugate is capable of increasing the delivery efficiency of a drug for hair loss treatment at a low concentration, and is thus very effective at treating androgenic alopecia.

Abstract: An acoustic wave medical treatment of a body part of an individual in which nanoparticles are administered to the body part of the individual and the acoustic wave is applied on the body part. The acoustic wave is sequentially applied on the body part, and/or the nanoparticles are magnetosomes. Also, compositions that include these nanoparticles.

Abstract: The present invention is directed to a liposome composition for use in the peritoneal dialysis of patients suffering from endogenous or exogenous toxicopathies, wherein the pH within the liposomes differs from the pH in the intraperitoneal cavity and wherein the pH within the liposome results in a liposome-encapsulated charged toxin. The invention also relates to a pharmaceutical composition comprising said liposomes. A further aspect of the present invention relates to a method of treating patients suffering from endogenous or exogenous toxicopathies, preferably selected from drug, metabolite, pesticide, insecticide, toxin, and chemical warfare toxicopathies, more preferably hyperammonemia, comprising the step of administering liposomes of the invention in a therapeutically effective amount into the peritoneal space of a patient in need thereof. Next to human, the present invention is particularly suitable to veterinary aspects.

Abstract: Multi-phase oral care compositions for whitening teeth, including hydrophilic bleaching agent particles in a hydrophobic phase with a melting point of from about 40° C. to about 80° C. The hydrophilic bleaching agent particles can include peroxide compounds and/or hydrogen peroxide adducts. The hydrophilic bleaching agent particle can have a solubility in water of at least about 20 parts, by weight of the particles, in about 100 parts, by weight, of water.

Abstract: The present invention encompasses prodrug compositions, nanoparticles comprising one or more prodrugs, and methods of use thereof.

Abstract: This disclosure describes a process for preparing silica-coated calcium carbonate particles, involving the steps of preparing an aqueous carbonate slurry containing calcium carbonate particles, adding at least one silicate composition to the aqueous carbonate slurry to obtain a carbonate-silicate slurry, lowering a pH of the carbonate-silicate slurry by adding at least one acidic compound to obtain a pH-adjusted slurry containing the silica-coated calcium carbonate particles, and isolating the silica-coated calcium carbonate particles—in which at the adding of the acidic compound is controlled such that a final pH of the pH-adjusted slurry ranges from about 7 to about 10, and the silica-coated calcium carbonate particles include a porous coating having an average pore diameter ranging from 2 nm to 50 nm. This disclosure also describes articles and compositions containing the silica-coated calcium carbonate particles, as well as hollow silica spheres formed from the silica-coated calcium carbonate particles.

Abstract: The subject technology relates generally to pulmonary delivery of NSAIDs, such as aspirin.

Abstract: Lipid-based vesicles, typically herein called transfection competent vesicles (TCVs), configured to safely and efficiently deliver DNA, RNA, other nucleic acid and protein cargoes into target cells. The safety and efficiency are each, and both, achieved in part by eliminating organic solvents such as ethanol and detergents such as sodium dodecyl sulfate from the TCV loading processes (i.e., inserting a cargo into the TCV), TCV storage processes, and/or TCV delivery processes. The cargoes can also comprise nucleic acids complexed with a protein, such as a ribonucleoprotein (RNP). The systems, compositions, devices and methods, etc., herein, in some embodiments, can provide empty TCVs that can if desired be loaded at the bench without use of specialized equipment.

Abstract: The present disclosure relates to a nanoparticle complex that is taken into cells to be used for the treatment of diseases, and a method of manufacturing the same using a top-down process. In the top-down process, surfaces of nanoparticles are modified with a lipid-based material having high stability and excellent biocompatibility, thereby improving endocytosis efficiency. A lipid structure having a tube shape is bonded to a portion of the surface of the nanoparticle, so that the nanoparticle complex undergoes endocytosis, directly penetrates a cell membrane, and is effectively taken into spheroid-type tumor cells. The lipid structure is not directly attached to the nanoparticles, lipid-based lipidomes (such as bubbles and liposomes) are bonded to the nanoparticles, and mechanical force is applied thereto to thus crush the lipidomes, so that the lipid structure is formed on the surface of the nanoparticle.

Abstract: A method of synthesizing silymarin-loaded collagen collagen nanoparticles can include dissolving silymarin in an alcohol to provide a solution, mixing the solution with acetic acid to provide an acetic acid mixture, and adding the glutaraldehyde to the mixture to provide silymarin nanoparticles. The silymarin nanoparticles can be dissolved in a further alcohol and mixed for a period of time to provide a silymarin nanoparticle mixture. Then, the silymarin nanoparticles can be mixed with collagen nanoparticles to provide a silymarin/collagen mixture. Glutaraldehyde can be added to the collagen mixture to provide the nanocomposite formulation.

Abstract: A nanomedicinal composition comprising a nanocarrier and an antioxidant. The nanocarrier contains a metal organic framework and a porous silicate and/or aluminosilicate matrix. The antioxidant is disposed in the pores and/or on the surface of the nanocarrier by a solution phase impregnation process. The nanomedicinal composition is used in a method of treating Blastocystis infection.

Abstract: Disclosed is a dissolvable solid article, comprising by weight of the article: from about 10% to about 50% of a water soluble polymer; from about 20% to about 80% of a surfactant; from about 0.5% to about 2% of diaminocarboxylic acid chelants and salts thereof having an average molecular weight in acid form of from about 250 to about 450 daltons and having a weighted log P value at pH 4 of from about ?12 to about ?7; from about 0.1% to about 6% of an aromatic carboxylic acid and salts thereof having an average molecular weight in acid form of from about 100 to about 400 daltons and having a weighted log P value at pH 4 of from about ?2 to about 4; from about 0.1% to about 18% of an non-aromatic organic alpha hydroxy acid and salts thereof; wherein the dissolvable solid article has a pH of from about 3 to about 5.1 when dissolved with 30 parts water to 1 part of the dissolvable solid article.